Conclusion:
Currently Nine trials (Table-2) on Remdesivir are ongoing to evaluate its safety and efficacy in the treatment of Covid 19. Results of these clinical trials will provide crucial information about whether remdesivir represents a viable treatment option for COVID-19 . While there is limited information known about the safety and effectiveness of using remdesivir to treat people in the hospital with COVID-19, the investigational drug was shown in clinical trial to shorten the time to recovery in some patients.[16] If the trial findings are ultimately positive, it will be imperative to ensure that the drug is produced on a commercial scale capable of meeting the demand generated by both the current pandemic and future outbreaks.
References:
  1. Center for Health Security. The characteristics of pandemic pathogens.cited Mar 4, 2019. Available from:http://www.centerforhealth security.org/our-work/pubs_archive/pubs-pdfs/2018/180510-pandemic-pathogens-report.pdf.
  2. R.N. Kirchdoerfer, A.B. Ward, Structure of the SARS-CoV nsp12 polymerase bound to nsp7 and nsp8 co-factors, Nat. Commun. 10 (1) (2019) 2342,
  3. Cj G, Ep T, Jy F, et al. The antiviral compound remdesivir potently inhibits RNAdependent RNA polymerase from Middle East respiratory syndrome coronavirus. J Biol Chem 2020.
  4. E. de Wit, F. Feldmann, J. Cronin, R. Jordan, A. Okumura, T. Thomas, et al., Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection, Proc. Natl. Acad. Sci. U. S. A. (2020),
  5. Sheahan TP, Sims AC, Leist SR, Schäfer A, Won J, Brown AJ et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun. 2020:10;11(1):222.
  6. B.G. Murphy, M. Perron, E. Murakami, K. Bauer, Y. Park, C. Eckstrand, et al., The nucleoside analog GS-441524 strongly inhibits feline infectious peritonitis (FIP) virus in tissue culture and experimental cat infection studies, Vet. Microbiol. 2018;219: 226–233
  7. N.C. Pedersen, M. Perron, M. Bannasch, E. Montgomery, E. Murakami, M. Liepnieks, et al., Efficacy and safety of the nucleoside analog GS-441524 for treatment of cats with naturally occurring feline infectious peritonitis, J. Feline Med. Surg. 2019; 21(4): 271–81
  8. Lo MK, Feldmann F, Gary JM, Jordan R, Bannister R, Cronin J et al. Remdesivir (GS-5734) protects African green monkeys from Nipah virus challenge. Sci Transl Med. 2019; 29;11(494). pii: eaau9242
  9. Lo MK, Jordan R, Arvey A, Sudhamsu J, Shrivastava-Ranjan P, Hotard AL et al. GS-5734 and its parent nucleoside analog inhibit Filo-, Pneumo-, and Paramyxoviruses. Sci Rep. 2017;7:43395
  10. Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res . 2020;30(3):269‐71
  11. Levine MM. Monoclonal Antibody Therapy for Ebola Virus Disease. N Engl J Med 2019; 381:2365-6
  12. Mulangu S, Dodd LE, Davey RT Jr, Tshiani Mbaya O, Proschan M, Mukadi D et al. A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics. N Engl J Med. 2019;381(24):2293-303
  13. Jacobs M, Rodger A, Bell DJ, Bhagani S, Cropley I, Filipe A, et al. Late Ebola virus relapse causing meningoencephalitis: a case report. Lancet. 2016;338: 498–503
  14. Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial.Lancet .2020;395:1569-78
  15. Gilead Announces Results From Phase 3 Trial of Investigational Antiviral Remdesivir in Patients with Severe COVID-19 [news release]. Foster City, CA; April 29, 2020: Gilead Sciences.
  16. US Food & Drug Administration (FDA). Coronavirus (COVID-19) Update: FDA Issues Emergency Use Authorization for Potential COVID-19 Treatment. FDA News Release. 1st May 2020. (https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-issues-emergency-use-authorization-potential-covid-19-treatment)
  17. “Summary on Compassionate Use: Remdesivir Gilead” (https://www.ema.europa.eu/en/documents/other/summary-compassionate-use-remdesivir-gilead_en.pdf) (PDF). European Medicines Agency. Retrieved 1 May 2020
  18. Warren TK, Jordan R, Lo MK, Ray AS, Mackman RL, Soloveva V et al. Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature. 2016;531(7594):381-5
  19. Summaries of evidence from selected experimental therapeutics. 2018 as of October https://www.who.int/ebola/drc-2018/summaries-of-evidenceexperimental- therapeutics.pdf?ua=1